San Francisco, California, May 03, 2018: The widespread drive for humanized mouse models has stemmed from the substantial need for robust pre-clinical animal models for the study of a spectrum of human diseases. These animal models are proving to be promising in closely reflecting human biological systems. The rising clinical use of humanized mice in expanding our understanding of cancer therapies, regenerative medicine, allergies, and immunity-related diseases is propelling the growth of the market.
To shed in-depth light on such trends and factors influencing the growth trajectory of the market, TMR Research has published a new report, titled, “Humanized Mouse Model Market – Global Industry Analysis, Size, Share, Trends, Analysis, Growth, and Forecast 2017–2025.”
The attractive demand for humanized mice models for pre-clinical tools for biomedical research to discover more efficacious drugs is boosting the market. The rise in strategic mergers and acquisitions entered by pharmaceutical companies in various parts of the world to boost drug discovery activities is fortifying the demand for these cutting-edge platforms. The sizeable funds and grants committed by governments in several countries for research and development activities related to humanized model is providing a robust catalyst to the demand.
The growth of the humanized mouse models market is expected to reflect well from the rising efforts by pharmaceutical and biotech companies in personalized medicines. The growing adoption of mouse models with humanized immune systems to act as in vivo platform for assessing the efficacy of new drugs is also propelling the market’s growth. They prove to be useful in-vivo models for graft rejection research. Furthermore, the notably rising demand for cell-based humanized mouse models in genetic studies world over is accentuating the market.
Get Sample Copy of this Report @
Some of the prominent players holding a substantial stake in the global humanized mouse models market are The Jackson Laboratory, Harbour Antibodies BV, HuMurine Technologies, Inc., Ingenious Targeting Laboratory, Axenis S.A.S, GenOway S.A., and Horizon Discovery Group PLC.